Literature DB >> 15772572

Percutaneous administration of progesterone: blood levels and endometrial protection.

Frank Z Stanczyk1, Richard J Paulson, Subir Roy.   

Abstract

There is controversy about the beneficial effects of topical progesterone creams used by postmenopausal women. A major concern is that serum progesterone levels achieved with progesterone creams are too low to have a secretory effect on the endometrium. However, antiproliferative effects on the endometrium have been demonstrated with progesterone creams when circulating levels of progesterone are low. Thus, effects of topical progesterone creams on the endometrium should not be based on serum progesterone levels, but on histologic examination of the endometrium. Despite the low serum progesterone levels achieved with the creams, salivary progesterone levels are very high, indicating that progesterone levels in serum do not necessarily reflect those in tissues. The mechanism by which the serum progesterone levels remain low is not known. However, one explanation is that after absorption through the skin, the lipophilic ingredients of creams, including progesterone, may have a preference for saturating the fatty layer below the dermis. Because there appears to be rapid uptake and release of steroids by red blood cells passing through capillaries, these cells may play an important role in transporting progesterone to salivary glands and other tissues. In contrast to progesterone creams, progesterone gels are water-soluble and appear to enter the microcirculation rapidly, thus giving rise to elevated serum progesterone levels with progesterone doses comparable to those used in creams.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772572     DOI: 10.1097/00042192-200512020-00019

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  5 in total

Review 1.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

Review 2.  Actions of progestins for the inhibition of cervical ripening and uterine contractions to prevent preterm birth.

Authors:  R-J Kuon; R E Garfield
Journal:  Facts Views Vis Obgyn       Date:  2012

3.  Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.

Authors:  James H Pickar; Charles Bon; Julia M Amadio; Sebastian Mirkin; Brian Bernick
Journal:  Menopause       Date:  2015-12       Impact factor: 2.953

4.  Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).

Authors:  Rogerio A Lobo; James Liu; Frank Z Stanczyk; Ginger D Constantine; James H Pickar; Annette M Shadiack; Brian Bernick; Sebastian Mirkin
Journal:  Menopause       Date:  2019-07       Impact factor: 2.953

5.  Bioidentical hormones for menopausal hormone therapy: variation on a theme.

Authors:  Adriane Fugh-Berman; Jenna Bythrow
Journal:  J Gen Intern Med       Date:  2007-03-07       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.